Adjuvant Immune CheckPoint InhibitoRs Based ThErapy in PostoperatiVe HEpatocellular CarciNoma: a ProspecTive Real-world Study
Status: Completed
Location: See location...
Intervention Type: Drug, Other
Study Type: Observational
SUMMARY
Though hepatectomy is the best treatment for patients with hepatocellular carcinoma (HCC), the 5-years recurrence-free survival is lower than 30%. In recent years, several immune checkpoint inhibitors have been approved in advanced HCC. No study about the safety and efficacy of adjuvant immune checkpoint inhibitors for patients with HCC after hepatectomy was reported.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Underwent curative hepatectomy;
• Diagnosis of HCC was confirmed by postoperative histopathology;
• Liver function Child-Pugh A or B;
• Performance status score 0 or 1
• With high risk factor of HCC recurrence, such as tumor size ≥ 5 cm, multinodular, macrovascular invasion or microvascular invasion; Receive immune checkpoint inhibitors based adjuvant therapy.
Locations
Other Locations
China
Jian-Hong Zhong
Nanning
Time Frame
Start Date: 2019-03-03
Completion Date: 2023-03-17
Participants
Target number of participants: 517
Treatments
Immune checkpoint inhibitors based adjuvant therapy
Patients in this arm will receive immune checkpoint inhibitors based adjuvant therapy.
Without adjuvant therapy
Patients in this arm will not receive any adjuvant therapy.
Related Therapeutic Areas
Sponsors
Leads: Guangxi Medical University